SAGA Diagnostics stärker teamet

SAGA Diagnostics AB, ett diagnostikbolag med ultrakänslig metod för icke-invasiv monitorering av cancerpatienter, utökar nu sitt team. Bolaget har anställt fyra personer för att fortsätta att accelerera kommersialisering och utveckling av sin unika produkt vilken etableras allt mer på marknaden. De fyra nya är Annina Hube, PhD MBA, som Director of Market Access, Rocco Crescenzo, MD som Chief Medical Officer, samt Maria Fe Paz, MD PhD MBA och Florian Eckhardt, PhD MBA som Strategic Advisors.


SAGA Diagnostics är medlem i SmiLe Incubator samt portföljbolag i LU Holding, Lunds universitets holdingbolag, och är baserat på Medicon Village i Lund.


(Resten av pressmeddelandet är på engelska:)

SAGA EXPANDS WITH FOUR NEW TEAM MEMBERS TO FURTHER ACCELERATE COMMERCIAL AND MEDICAL DEVELOPMENT

SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the appointment of four people to significantly strengthen SAGA’s team: Annina Hube, PhD MBA, as Director of Market Access, Rocco Crescenzo, MD as Chief Medical Officer,  and Maria Fe Paz, MD PhD MBA and Florian Eckhardt, PhD MBA as Strategic Advisors. 

"We are extremely pleased to add such strength to our fast-growing team. Annina, Rocco, Maria, and Florian join at just the right moment, with expertise and experience that are instrumental for our ambitious expansion plans in this next phase of SAGA", says Lao Saal, co-founder and CEO, SAGA Diagnostics.

Dr. Hube brings an in-depth knowledge from both the regulatory and market aspects of IVDs, especially in the NGS and liquid biopsy fields. Prior to joining SAGA, Annina served in BD, supply chain, logistics, and marketing roles for four years at NEO New Oncology GmbH.  Previously, Annina has also held senior marketing positions at both Abcam in Cambridge, UK, and Vela Diagnostics in Hamburg, Germany.Her main responsibility at SAGA will be to direct the market access activities in the European market.

Dr. Crescenzo is an experienced medical officer, having served in global clinical and regulatory leadership roles in the US and UK at Pfizer, Novartis, and GlaxoSmithKline, where he helped to advance a number of clinical programs in oncology.  He is licensed in the UK and USA, board certified in internal medicine and medical oncology, and was formerly the co-director of the Temple University Cancer Center.  Rocco will be responsible for SAGA’s clinical development program including the launch of new clinical trials.

Dr. Fe Paz joins SAGA with over 15 years of outstanding technical, entrepreneurial, and leadership experience in molecular diagnostics and precision medicine.  She is President and CMO of Inflection Point Biomedical Advisors, General Partner of Article25 Capital, and the former CMO for Rosetta Genomics.  For more than 5 years, she also was founder and president of Labceutics and CMO for the Diaceutics Group.  Maria will support SAGA in strategic decisions relating to clinical trials and commercial expansion.

Dr. Eckhardt is seasoned executive in medical diagnostics, since 2003 having worked in senior management and BD roles at companies such as Epigenomics AG, and ThermoFisher Scientific, as well as being the CEO of DST Diagnostische und Technologien GmbH from 2013-2018.  He is also a senior investment director at Hadean Ventures, and previously was an investment manager at Inventages.  Florian will support SAGA in strategic analyses relating to commercial partnering and entering new markets.

 

Contact: CEO Lao Saal, MD PhD.   media@sagadiagnostics.com   Phone: +46 (0) 733 01 7242

About SAGA Diagnostics AB

SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and provides the basis for optimal decision-making. 

 

---

---